178 results were returned
In Australia the application of the Patent Term Extension provisions of the Patents Act 1990 have been construed narrowly so that PTEs are applicable to only certain types of pharmaceutical patents.
Late last week, the Full Federal Court of Australia confirmed that the mere act of filing a Pharmaceutical Benefits Scheme (PBS) application for a generic pharmaceutical product is not, of itself, an act of infringement ...
Australia has long lagged behind the USA and UK in its use of generic pharmaceuticals – only around 58% of medicines dispensed in Australia are the generic versus up to 80% in the USA and UK.
It has been clear for some time now that the European Medicines Agency (EMA), based in Canary Wharf, London since its establishment in 1995, will be relocated to another EU Member State as a result of the UK’s decision ...
On 10 November 2017, Henry Carr J in the English Patents Court delivered a significant decision which will be of great interest to litigants in the field of generic pharmaceuticals.
The Actavis v Eli Lilly decision of the UK Supreme Court has been described by some commentators as being a minor gloss on the law of patent infringement and claim scope.
The rules for clinical trials on medicinal products for human use are to change early next year. There is currently a draft bill before the Slovak Government aimed at reflecting and implementing the EU Regulation on ...
It is common practice that patentees obtain evidence directly from the price and reimbursement authority on the planned launch date of a generic product by requesting disclosure of the application for price ...